Humanwell Healthcare (Group) Co. Ltd. has disclosed Mas-related G-protein coupled receptor member X4 (MRGPRX4; SNSR5; SNSR6) antagonists reported to be useful for the treatment of pruritus.
Fibrobiologics Inc. has received public and private Human Research Ethics Committee (HREC) approvals in Australia for a phase I/II trial evaluating CYWC-628 for the treatment of refractory diabetic foot ulcers.
Crossbridge Bio Inc. has been awarded a $15 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to support completion of IND-enabling activities and advancement of CBB-120 into first-in-human studies.
Scineuro Pharmaceuticals Holdings Ltd. has received a $5 million research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to accelerate the preclinical development of the company’s novel LRRK2-targeted antisense oligonucleotide (ASO) program, SNP-614, for Parkinson’s disease.
Human endogenous retroviruses (HERVs) are residues from ancient viral infections that have become integrated into the human genome. One of them – HERV-K – is aberrantly reactivated in solid tumors but silent in healthy tissues.
Researchers at Tubulis GmbH reported preclinical efficacy data on TUB-030, a novel 5T4-targeting antibody-drug conjugate (ADC), in several sarcoma subtypes.
Heart failure with preserved ejection fraction (HFpEF) is a complex disease with limited therapeutic options. Protein histone deacetylase 6 (HDAC6) is known to be involved in several biological processes, such as autophagy or inflammation, among others, but its impact on HFpEF has not been well evaluated to date.
Revir Therapeutics Inc. has announced progress in its HTT-PMS1 genetic medicine program for Huntington’s disease with the identification of a lead compound and the award of a $4.6 million grant from the California Institute for Regenerative Medicine (CIRM).
Evaxion A/S is advancing its cytomegalovirus (CMV) vaccine program, EVX-V1, with new data demonstrating protective effects of lead antigens in the program. EVX-V1 is a next-generation, multicomponent vaccine program combining novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens.
RSS
